HOME Tuesday, January 6, 2009
What’s the next big thing
in drug development?
Here at Cognigen, we have a pretty good idea of where the pharmaceutical field is heading. And let us tell you, it’s some pretty exciting stuff. Get a glimpse of our vision by reading our manifesto on the transition to model-based drug development. While you’re at it, you can also learn why we’re such strong advocates of formalizing the pharmacometrics process.
Besides writing astute articles, we’re also pioneering the industry by offering expanded data assembly and programming services. At this point, you’re probably thinking, “Golly, that’s interesting! How can I learn more?” It’s simple. Sign up for our workshop on engineering pharmacometrics. And for the latest updates and insights, you’ll certainly want to peruse our blog. We predict you’ll find it quite enlightening.
Join us.
Help blaze the trail in drug development. Work with some of the brightest minds in the business. Feel the camaraderie of a tight-knit team. Build your career. Share in a good laugh or two. It’s all in a day’s work here at Cognigen. Like what you hear? READ MORE
Kerfuffle! (part 1)
FROM SECTION: Blog
\kәr-’fә-fәl\ to become disheveled. A kerfuffle is the polite term for a cascading series of errors that can be initiated by a seemingly innocuous event that then leads to other errors that gain in severity and impact. This essay describes a strategy for eradicating or minimizing the impact of kerfuffles in pharmacometrics. READ MORE
Beauty and the Beast?
FROM SECTION: Blog
Several large Pharma companies have announced interest in acquiring small biotech companies. Many Pharma companies have reduced or eliminated drug discovery efforts, and with stock prices back at 2003 levels, there certainly is a great deal of sense in these acquisitions. But finding another way to integrate these companies and their development portfolio also makes a great deal of sense. READ MORE